Chitosan Grafted Poly (Ethylene Glycol) Methyl Ether Acrylate Particulate Hydrogels for Drug Delivery Applications.
biomedical applications
chitosan particulate hydrogels
double crosslinking
levofloxacin
poly (ethylene glycol) methyl ether acrylate
Journal
Gels (Basel, Switzerland)
ISSN: 2310-2861
Titre abrégé: Gels
Pays: Switzerland
ID NLM: 101696925
Informations de publication
Date de publication:
09 Aug 2022
09 Aug 2022
Historique:
received:
08
07
2022
revised:
01
08
2022
accepted:
05
08
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Chitosan (CS) crosslinking has been thoroughly investigated, but the chemical reactions leading to submicronic hydrogel formulations pose problems due to various physical/chemical interactions that limit chitosan processability. The current study employs the chemical modification of chitosan by Michael addition of poly (ethylene glycol) methyl ether acrylate (PEGA) to the amine groups to further prepare chitosan particulate hydrogels (CPH). Thus, modified CS is subjected to a double crosslinking, ionic and covalent, in water/oil emulsion. The studied process parameters are polymer concentration, stirring speed, and quantity of ionic crosslinker. The CPH were structurally and morphologically characterized through infrared spectroscopy, scanning electron microscopy, light scattering granulometry, and zeta potential, showing that modified CS allows better control of dimensional properties and morphology as compared with neat CS. Swelling properties were studied in acidic and neutral pH conditions, showing that pH-dependent behavior was maintained after grafting and double crosslinking. The applicability of the prepared materials was further tested for drug loading and in vitro delivery of levofloxacin (LEV), showing excellent capacity. CPH were found to be cyto- and hemocompatible demonstrating their potential for effective use as a controlled release system for different biomedical applications.
Identifiants
pubmed: 36005095
pii: gels8080494
doi: 10.3390/gels8080494
pmc: PMC9407074
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : UEFISCDI
ID : PCE 115/2022
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Curr Ther Res Clin Exp. 2003 Nov;64(9):646-61
pubmed: 24944413
J Control Release. 2014 Sep 28;190:31-2
pubmed: 25356469
Membranes (Basel). 2010 Dec 15;1(1):3-12
pubmed: 24957491
Rom J Morphol Embryol. 2014;55(3):869-75
pubmed: 25329114
Int J Biol Macromol. 2016 Nov;92:561-572
pubmed: 27451027
ACS Omega. 2020 Aug 10;5(32):20450-20460
pubmed: 32832798
Carbohydr Polym. 2016 Oct 20;151:488-499
pubmed: 27474593
Carbohydr Polym. 2018 Jul 15;192:104-110
pubmed: 29691001
J Control Release. 2004 Nov 5;100(1):5-28
pubmed: 15491807
J Pharm Sci. 2006 Jun;95(6):1173-6
pubmed: 16639718
J Drug Target. 2011 Jul;19(6):409-17
pubmed: 20678034
Int J Biol Macromol. 2016 Jun;87:237-45
pubmed: 26930578
Biomed Res Int. 2014;2014:951942
pubmed: 25162037
Biomacromolecules. 2020 Mar 9;21(3):1285-1294
pubmed: 32053355
Carbohydr Polym. 2018 Aug 1;193:163-172
pubmed: 29773368
Langmuir. 2012 Oct 23;28(42):15056-64
pubmed: 23036055
Int J Biol Macromol. 2020 Dec 15;165(Pt B):2205-2218
pubmed: 33058982
Gels. 2017 Jan 24;3(1):
pubmed: 30920503
Carbohydr Polym. 2014 Sep 22;110:113-20
pubmed: 24906736
Int J Pharm. 2012 Oct 15;436(1-2):66-74
pubmed: 22721854
Mater Sci Eng C Mater Biol Appl. 2019 May;98:843-860
pubmed: 30813091
Nanomaterials (Basel). 2015 Dec 03;5(4):2054-2130
pubmed: 28347111
Biomaterials. 1999 Oct;20(20):1869-78
pubmed: 10514063
Polymers (Basel). 2021 Sep 24;13(19):
pubmed: 34641071